AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Moderna, Inc. Director's Dealing 2020

Mar 3, 2020

30610_dirs_2020-03-03_190ee78d-e0bd-499a-a9b7-5749eae8ebb5.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2020-02-28

Reporting Person: Kim Lorence H. (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-02-28	Stock Option (Right to Buy)	$25.93	A	179022	Acquired	2030-02-28	Common Stock (179022)	Direct

Footnotes

F1: 25% of this option will vest and become exercisable on February 28, 2021 with the remainder vesting in twelve (12) equal quarterly installments thereafter.